Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases
Proceeds support a product pipeline with multiple AAV-based gene therapies with disease-modifying potential and creation of a company-owned AAV manufacturing facility
NEW YORK, February 12, 2019-- Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing. Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed leading healthcare investment fund.
Neurogene’s mission is to improve patient outcomes by advancing genetic medicines for many neurological disorders for which the company may make a tangible, life-altering difference. Neurogene partners with leading academic researchers, patient advocacy organizations and caregivers to bring therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today.
“Neurogene is reimagining the future for patients with rare neurological diseases and their families,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer. “Through partnerships and our own internal expertise, we are advancing our gene therapy programs for rare neurological disorders. The vast majority of rare diseases remain unaddressed, and our goal is to enable a better future for patients with these diseases.”
With the funding announced today, Neurogene will advance multiple gene therapy programs into IND-enabling studies and clinical trials for patients with rare neurological diseases, invest in novel technologies for indications not addressed by traditional gene therapy approaches and establish a viral vector manufacturing facility.
About Neurogene, Inc.
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technologies to develop treatments for diseases not well served by gene therapy. For more information, visit www.neurogene.com.
Sara Green, Ten Bridge Communications
Venture Capital Database